Fusobacterium Nucleatum Empyema: An Atypical Presentation

Lucía Barrera-López1, Cristina Macía-Rodríguez2, Lucía Ferreiro-Fernández3, José Antonio Díaz-Peromingo1

1Department of Internal Medicine, Complexo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain
2Department of Internal Medicine, POViSA Hospital, Vigo, Spain
3Department of Pulmonology, Complexo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain

Received: 22/03/2020
Accepted: 31/03/2020
Published: 24/04/2020

How to cite this article: Barrera-López L, Macía-Rodríguez C, Ferreiro-Fernández L, Díaz-Peromingo JA. Fusobacterium nucleatum empyema: an atypical presentation. EJCRIM 2020;7: doi:10.12890/2020_001631.

Conflicts of Interests: The Authors declare that there are no competing interests.
This article is licensed under a Commons Attribution Non-Commercial 4.0 License

ABSTRACT
A 40-year-old man presented to the emergency room and was evaluated in the internal medicine department for unexplained weight loss, asthenia, anorexia and night sweats over the previous 2 months. After a loculated pleural effusion was identified on thoracic computed tomography, purulent fluid was drained from the lung and Fusobacterium nucleatum was isolated. The patient was successfully treated for 27 days with amoxicillin-clavulanic acid. This was an atypical presentation of a common micro-organism implicated in lung infections.

LEARNING POINTS
- Empyema due to Fusobacterium nucleatum can have an atypical presentation, manifesting only with unexplained weight loss and night sweats.
- F. nucleatum lung infection usually responds well to treatment with common antibiotics.
- In patients with unexplained weight loss, the differential diagnosis should include cancer, tuberculosis and atypical presentations of other bacterial infections.

KEYWORDS
Fusobacterium nucleatum, empyema, unexplained weight loss

CASE DESCRIPTION
We present the case of a 40-year-old man who works in a cardboard factory. He has smoked 10 cigarettes a day since the age of 18. He was referred to an internal medicine consultation because of a 2-month history of an unexplained 9 kg weight loss with asthenia, anorexia and night sweats without fever or chest pain. He did not report recent contact with tuberculosis.

Physical examination revealed pale skin and cachexia. The oral cavity did not show any evidence of erosions, periodontitis, tooth loss or recent surgery. The patient was eupnoeic but had no vesicular breath sounds in the lower two-thirds of the left hemithorax and grade I splenomegaly. The rest of the physical examination was normal.

Blood analysis showed 10 410 leukocytes/µl (75.1% neutrophils, 15.8% lymphocytes), haemoglobin 11.1 g/dl, mean corpuscular volume 82.4 fl, erythrocyte sedimentation rate 37 mm, alkaline phosphatase 279 IU/l, ferritin 728 ng/ml, ultra-sensitive C-reactive protein >10 000 mg/dl, and elevation of alpha-1/alpha-2 globulins. Chest radiography demonstrated loss of volume in the left hemithorax with a probable extrapulmonary mass projecting into the upper segment of the inferior left lobe and associated pleural effusion (Fig. 1). Thoracic computed tomography showed a cystic lesion compatible with loculated pleural effusion in the left hemithorax (Fig. 2). Diagnostic thoracentesis removed approximately 100 ml of foul-smelling pus. Culture revealed multi-sensitive Fusobacterium nucleatum. Blood cultures were negative. A pleural drainage tube was placed, with instillation of urokinase and treatment with amoxicillin-clavulanic acid for 27 days, with good evolution (Fig. 3).
In the differential diagnosis, a lymphoproliferative process or a tuberculous loculated pleural effusion were considered the main possibilities. The patient was a daily smoker with no evidence of regular dental check-ups, so poor oral hygiene may have contributed to the condition.

**DISCUSSION**

*F. nucleatum* is an immobile, anaerobic Gram-negative bacterium. Lipopolysaccharide endotoxins found in the outer membrane facilitate adhesion and aggregation, allowing tissue invasion and increased virulence. The organism belongs to the Fusobacteraeaceae family (13 species), with *F. necrophorum* and *F. nucleatum* being the most common pathogens in humans. It is part of the oral commensal flora,[1](#) but can behave as a pathogen in several clinical entities.
The annual incidence of *Fusobacterium* infections is 0.6–3.5 cases per 1 million population \(^2\). This micro-organism can cause respiratory, oral, neurological, obstetric and skin infections. In addition, it is linked to colorectal cancer, inflammatory bowel disease and reactivation of latent human immunodeficiency virus-1 infection. It is one of the main causes of empyema. A Bulgarian study with 198 patients, found anaerobic bacteria in 147 (74.2%). *F. nucleatum* was detected in 27.2% of pleural fluid samples \(^3\), while Dyrhovden et al. reported that of 64 patients with empyema, 37 had an identified micro-organism, including *F. nucleatum* and/or *Streptococcus intermedius* \(^4\). Our patient’s only risk factor was his smoking habit. Diabetes mellitus, renal failure, dialysis, neoplasm and nosocomial infection have been identified as poor prognostic factors \(^1\).

Factors associated with empyema development include bacterial pneumonia, surgery or chest trauma, oesophageal perforation, thoracentesis, subdiaphragmatic infection, spontaneous pneumothorax, bacteraemia, and tobacco or alcohol use \(^3, 4\). Common clinical manifestations are cough, expectoration, chest pain or fever that can be linked with night sweats, asthenia, anorexia or weight loss. This is the first patient described in the literature who presented only with long-term unexplained weight loss and sweating. It is important to highlight the difficulty of isolating the micro-organism as it can be hard to obtain valid samples from the lower respiratory tract due to contamination by oral flora. The ideal culture medium is a selective agar called paromomycin-vancomycin Brucella HK. In addition, suboptimal cultivation methods can lead to an underestimation of *F. nucleatum* frequency \(^5\). *Fusobacterium* species are widely susceptible to antibiotics; however, mortality ranges between 4% and 20% depending on the series reviewed and type of *Fusobacterium*. In conclusion, empyema due to *Fusobacterium* can present atypically as unexplained weight loss with night sweats, without fever, cough or chest pain in patients without risk factors or immunosuppression. Antibiotic treatment is usually effective with a good prognosis in most cases.

**REFERENCES**

1. Yang CC, Ye JJ, Hsu PC, Chang HJ, Cheng CW, Leu HS et al. Characteristics and outcomes of *Fusobacterium nucleatum* bacteremia—a 6-year experience at a tertiary care hospital in northern Taiwan. *Diagn Microbiol Infect Dis* 2011;70:167–174.
2. Ahmed Z, Bansal SK, Dhillon S. Pyogenic liver abscess caused by *Fusobacterium* in a 21-year-old immunocompetent male. *World J Gastroenterol* 2015;21(12):3731–3735.
3. Boyanova L, Djambazov V, Gergova G, Iotov D, Petrov D, et al. Anaerobic microbiology in 198 cases of pleural empyema: a Bulgarian study. *Anaerobe* 2004;10(5):261–267.
4. Dyrhovden R, Nygaard RM, Patel R, Ulvestad E, Kommedal Ø. The bacterial aetiology of pleural empyema. A descriptive and comparative metagenomic study. *Clin Microbiol Infect* 2019;25(8):981–986.
5. Nagaoka K, Yanagihara K, Morinaga Y, Kohno S. Detection of *Fusobacterium nucleatum* in two cases of empyema and lung abscess using paromomycin-vancomycin supplemented Brucella HK agar. *Anaerobe* 2017;43:99–101.